R788

DRUG2 trials

Sponsors

Rigel Pharmaceuticals, Kissei Pharmaceutical Co., Ltd.

Conditions

Idiopathic Thrombocytopenic PurpuraRheumatoid Arthritis

Phase 2

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

CompletedNCT00326339

Rigel PharmaceuticalsRheumatoid Arthritis

Start: 2006-08-31End: 2007-12-31Updated: 2009-04-20

Phase 3

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

CompletedNCT04132050

Kissei Pharmaceutical Co., Ltd.Idiopathic Thrombocytopenic Purpura

Start: 2019-12-24End: 2023-09-25Updated: 2025-08-11